DK1004320T3 - Anvendelse af magnesium (Mg2+) til forbedring af genadministration ved genterapi - Google Patents

Anvendelse af magnesium (Mg2+) til forbedring af genadministration ved genterapi

Info

Publication number
DK1004320T3
DK1004320T3 DK99119057T DK99119057T DK1004320T3 DK 1004320 T3 DK1004320 T3 DK 1004320T3 DK 99119057 T DK99119057 T DK 99119057T DK 99119057 T DK99119057 T DK 99119057T DK 1004320 T3 DK1004320 T3 DK 1004320T3
Authority
DK
Denmark
Prior art keywords
gene
magnesium
administration
improve
gene therapy
Prior art date
Application number
DK99119057T
Other languages
English (en)
Inventor
Serge Braun
Original Assignee
Transgene Sa
Ass Fr Contre Les Myopathies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa, Ass Fr Contre Les Myopathies filed Critical Transgene Sa
Application granted granted Critical
Publication of DK1004320T3 publication Critical patent/DK1004320T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DK99119057T 1998-09-30 1999-09-30 Anvendelse af magnesium (Mg2+) til forbedring af genadministration ved genterapi DK1004320T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98402424A EP0998945A1 (en) 1998-09-30 1998-09-30 Use of magnesium (Mg2+) for the enhancement of gene delivery in gene therapy

Publications (1)

Publication Number Publication Date
DK1004320T3 true DK1004320T3 (da) 2003-09-15

Family

ID=8235506

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99119057T DK1004320T3 (da) 1998-09-30 1999-09-30 Anvendelse af magnesium (Mg2+) til forbedring af genadministration ved genterapi

Country Status (10)

Country Link
US (2) US20020019357A1 (da)
EP (2) EP0998945A1 (da)
JP (1) JP5172054B2 (da)
AT (1) ATE243531T1 (da)
AU (1) AU767294B2 (da)
CA (1) CA2284399C (da)
DE (1) DE69909041T2 (da)
DK (1) DK1004320T3 (da)
ES (1) ES2201611T3 (da)
PT (1) PT1004320E (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875748B2 (en) 2000-04-21 2005-04-05 Vical Incorporated Compositions and methods for in vivo delivery of polynucleotide-based therapeutics
EP1249244A1 (en) * 2001-04-13 2002-10-16 Universiteit Gent Therapeutic compositions for the treatment of a disease modulated by the G-actin / F-actin equilibrium, especially a respiratory tract disease
WO2003000908A1 (en) * 2001-06-21 2003-01-03 Ecole Polytechnique Federale De Lausanne A method for introducing a nucleic acid into a eukaryotic cell
EP1270733A1 (en) * 2001-06-21 2003-01-02 Ecole Polytechnique Federale De Lausanne Method for introducing a nucleic acid into a eukaryotic cell
JP4499035B2 (ja) * 2003-01-17 2010-07-07 秀樹 大野 遺伝子導入促進剤及びそれを含む遺伝子導入用組成物
AU2004263274B2 (en) 2003-07-21 2009-11-05 Transgene S.A. Novel multifunctional cytokines
DE102005007744A1 (de) * 2004-06-24 2006-01-19 Shf Communication Technologies Ag Planetengetriebe zur Kombination unterschiedlicher Energiequellen
GB0817393D0 (en) * 2008-09-23 2008-10-29 Givaudan Sa Flavour
EP2405959A4 (en) * 2009-03-13 2013-10-16 Univ Tufts METHODS, APPARATUSES AND KITS FOR INTRODUCING GENETIC MATERIAL INTO LIVING CELLS
US9657076B2 (en) 2012-10-23 2017-05-23 Emory University GM-CSF and IL-4 conjugates, compositions, and methods related thereto
WO2019222666A1 (en) * 2018-05-17 2019-11-21 University Of Florida Research Foundation, Incorporated Methods and compositions for using metal elements in aav gene therapy

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60188069A (ja) * 1984-03-08 1985-09-25 Nakano Vinegar Co Ltd 酢酸菌の環状ｄνａ導入法
US4798789A (en) * 1984-10-05 1989-01-17 Dnax Research Institute Of Molecular And Cellular Biology, Inc. cDNA clones coding for polypeptides exhibiting murine interleukin-2 activity
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5693622A (en) * 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
FR2710074B1 (fr) * 1993-09-15 1995-12-08 Rhone Poulenc Rorer Sa Gène GRB3-3, ses variants et leurs utilisations.
US5844107A (en) * 1994-03-23 1998-12-01 Case Western Reserve University Compacted nucleic acids and their delivery to cells
FR2724665B1 (fr) * 1994-09-16 1996-12-20 Rhone Poulenc Rorer Sa Procede de production de proteines recombinantes, plasmides et cellules modifiees
JPH08308573A (ja) * 1995-05-19 1996-11-26 Ube Ind Ltd 細胞への遺伝子導入方法及びそれに用いられるウィルス感染培地
AU7142796A (en) * 1995-10-02 1997-04-28 Erasmus University Rotterdam Diagnosis method and reagents
US5994316A (en) * 1996-02-21 1999-11-30 The Immune Response Corporation Method of preparing polynucleotide-carrier complexes for delivery to cells
US6544523B1 (en) * 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US5830698A (en) * 1997-03-14 1998-11-03 Idec Pharmaceuticals Corporation Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
FR2763958A1 (fr) * 1997-05-29 1998-12-04 Transgene Sa Produit de combinaison associant un acide nucleique a une substance desorganisant la matrice extracellulaire pour la therapie genique
WO1999056784A2 (en) * 1998-05-06 1999-11-11 Transgene S.A. Inprovements in gene therapy using compositions comprising a polynucleotide and a nuclease inhibitor or interleukin-10

Also Published As

Publication number Publication date
CA2284399C (en) 2011-01-18
ATE243531T1 (de) 2003-07-15
EP1004320A1 (en) 2000-05-31
DE69909041T2 (de) 2004-04-01
DE69909041D1 (de) 2003-07-31
US20020019357A1 (en) 2002-02-14
AU5139799A (en) 2000-04-06
JP5172054B2 (ja) 2013-03-27
US20020156045A1 (en) 2002-10-24
EP1004320B1 (en) 2003-06-25
AU767294B2 (en) 2003-11-06
US6881724B2 (en) 2005-04-19
PT1004320E (pt) 2003-10-31
CA2284399A1 (en) 2000-03-30
ES2201611T3 (es) 2004-03-16
JP2000143549A (ja) 2000-05-23
EP0998945A1 (en) 2000-05-10

Similar Documents

Publication Publication Date Title
GR3035797T3 (en) Compositions useful for transferring therapeutically active substances into a target cell, and their use in gene therapy
HUP9801207A2 (hu) Nukleinsavat tartalmazó készítmények, előállításuk és alkalmazásuk
DK1004320T3 (da) Anvendelse af magnesium (Mg2+) til forbedring af genadministration ved genterapi
GEP20022784B (en) Celecoxib Composition
WO1996021470A3 (en) Compositions of nucleic acid and viscosity-increasing polymers for use in gene therapy
ATE219363T1 (de) Lösliche prodrugs von paclitaxel
CA2346119A1 (en) A method of inducing or enhancing chondrogenesis with extracellular matrix containing gdf-5
IL82084A0 (en) 1,4-diazepines,their preparation and pharmaceutical compositions containing them
IL136101A (en) Pharmaceutical compositions containing azelaic acid
CA2231176A1 (en) Long active composition for rectal administration
ATE220912T1 (de) Herstellung von st1435 enthaltenden pharmazeutischen zusammensetzungen zur topischen verwendung
DE69420776D1 (de) Idebenone-haltige Zusammensetzungen zur Behandlung von M. Alzheimer
ES2180729T3 (es) Tratamiento terapeutico combinado de las patologias hiperproliferantes.
EA200600402A1 (ru) Клеточные стенки дрожжей для лечения или профилактики гипергликемии или для стабилизации уровня сахара в крови
NO158677C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive isoksazol-derivater.
AU557139B2 (en) Nitrosourea derivatives
ES2150305T3 (es) Composicion anhidra a base de lactulosa.
AU527523B2 (en) Hexahydro-1,4-oxazepines
DK0927031T3 (da) Farmaceutisk sammensætning indeholdende nimesulid til oral admnistration
BE1002099A3 (fr) Nouvelles quinazolinones tetracycliques, leur preparation et leur utilisation comme medicaments.
IT1291307B1 (it) Composizione farmaceutica atta al trattamento delle patologie neurodegenerative
AU2699195A (en) Biotin compounds for targetting tumors and sites of infection
CA2175337A1 (en) Method and Composition for Treatment of Patients Having Decompensated Liver Disease
IT1238210B (it) Esteri del cefamandolo nafato, procedimento per la loro preparazione erelative composizioni farmaceutiche.